

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssseptasel1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 28	CA/Caplus patent coverage enhanced
NEWS	3	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS	4	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	5	JUL 28	STN Viewer performance improved
NEWS	6	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	7	AUG 13	CA/Caplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	8	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	9	AUG 15	Caplus currency for Korean patents enhanced
NEWS	10	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS	11	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS	12	SEP 25	CA/Caplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS	13	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and Korean patents enhanced
NEWS	14	SEP 29	IFICLS enhanced with new super search field
NEWS	15	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS	16	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS	17	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS	18	OCT 07	Multiple databases enhanced for more flexible patent number searching
NEWS	19	OCT 22	Current-awareness alert (SDI) setup and editing enhanced
NEWS	20	OCT 22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS	21	OCT 24	CHEMLIST enhanced with intermediate list of pre-registered REACH substances
NEWS EXPRESS	JUNE 27 08	CURRENT WINDOWS VERSION IS V8.3,	
		AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.	
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 13:08:13 ON 18 NOV 2008

=> fil reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:08:32 ON 18 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2
DICTIONARY FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\STNEXP\Queries\10517264.str



chain nodes :
10
ring nodes :
1 2 3 4 5 6 7 8 9
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
2-3 2-7 3-9 7-8 8-9
normalized bonds :
1-2 1-6 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 13:08:49 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 47727 TO ITERATE

4.2% PROCESSED 2000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 941495 TO 967585
PROJECTED ANSWERS: 131546 TO 141452

L2 50 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 13:08:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 951522 TO ITERATE

100.0% PROCESSED 951522 ITERATIONS 136136 ANSWERS
SEARCH TIME: 00.00.16

L3 136136 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 178.36 178.57

FILE 'CAPLUS' ENTERED AT 13:09:18 ON 18 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Nov 2008 VOL 149 ISS 21
FILE LAST UPDATED: 17 Nov 2008 (20081117/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 13

L4 38569 L3

=>

=> s 14 and pharmaceutical

316557 PHARMACEUTICAL

92562 PHARMACEUTICALS

371957 PHARMACEUTICAL

(PHARMACEUTICAL OR PHARMACEUTICALS)

L5 3160 L4 AND PHARMACEUTICAL

=> s 15 and arthritis

54947 ARTHRITIS

2 ARTHRITISES

54947 ARTHRITIS

(ARTHRITIS OR ARTHRITISES)

L6 214 L5 AND ARTHRITIS

=> s 16 and rheumatoid

39150 RHEUMATOID

11 RHEUMATOIDIS

39154 RHEUMATOID

(RHEUMATOID OR RHEUMATOIDIS)

L7 154 L6 AND RHEUMATOID

=> s 17 and cytokine

120584 CYTOKINE

158413 CYTOKINES

209557 CYTOKINE

(CYTOKINE OR CYTOKINES)

L8 20 L7 AND CYTOKINE

=> d ibib abs hitstr tot

THE ESTIMATED COST FOR THIS REQUEST IS 109.00 U.S. DOLLARS


DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

LS ANSWER 3 OF 20 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)
 ACCESSION NUMBER: 2007115955 CAPLUS
 DOCUMENT NUMBER: 14748410
 TITLE: Thiopyrimidines having Hx1/Hx2 inhibiting activity
 INVENTOR(S): for pharmaceutical compositions
 Alcher, Isabella; Conter, Thomas; Stephan, Jankel, Stefan; Seiler, Arndt-Klaus; Muffli, Stephan; Reuter, Tobias; Taylor, Steven
 PATENT ASSIGNER(S): Developpe Aktiengesellschaft, Germany
 SOURCE: PCT Int. Appl., 3pp.
 COMID: P16302
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
MO 2007115522	A1	20071018	MO 2007-EP3196	20070410
US 14748410	A1	20071018	US 2007-087439	20070410
CA, CN, CO, CH, CY, CZ, DE, DK, DM, ES, EG, FR, GB, GR, HU, IL, IN, JP, KR, MA, MD, ME, MG, MK, MN, MU, MY, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, RU, SA, SG, SI, SK, SL, SM, SN, SV, TH, TN, TR, TT, UA, US, VE, VN, ZA, ZM, ZW				
BR A12	BR	20070828	BR 06/000,352	20070828
EP 27, 17, 19, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100				

PRIORITY APPL. INFO.: EP 2006-7454 A 20060407

OTHER SOURCE(S): MARPAT 14748410
 AS The present invention relates to novel pharmaceutical compounds. Moreover, the present invention relates to the use of the thiopyrimidine compds. of the invention for the production of pharmaceutical compds. for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Hx1 and/or Hx2 (Hx1a or Hx2a) and/or variants thereof. The present invention is more particularly directed to the treatment and/or prophylaxis of in particular metabolic diseases of the lipid and carboxyacid metabolism and the consecutive complications and disorders associated therewith.
 IT 144701-4-4 CAPLUS
 RI PAC (Pharmaceutical activity); 780 (Therapeutic use); 810L (Biological study); USES (Uses)
 (Thiopyrimidines having Hx1/Hx2 kinase inhibiting activity for pharmaceutical compds. for treating disease and combination with other agents)
 RU 144701-4-4 CAPLUS
 CH [1,1'-Biphenyl]-2-carboxylic acid, 4'-(1,4'-dimethyl-2'-propyl)-2,6'-bi-18-benzimidazol-1'-ylmethyl]- (CA INDEX NAME)




REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE IE
 FORMAT

LS ANSWER 4 OF 20 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)
 ACCESSION NUMBER: 2007115955 CAPLUS
 DOCUMENT NUMBER: 14748410
 TITLE: Thiopyrimidines having Hx1/Hx2 inhibiting activity
 INVENTOR(S): for pharmaceutical compositions
 Alcher, Isabella; Conter, Thomas; Stephan, Jankel, Stefan; Seiler, Arndt-Klaus; Muffli, Stephan; Reuter, Tobias; Taylor, Steven
 PATENT ASSIGNER(S): Developpe Aktiengesellschaft, Germany
 SOURCE: PCT Int. Appl., 3pp.
 COMID: P16302
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
MO 2007112093	A1	20071004	MO 2007-087439	20070410
US 14748410	A1	20071018	US 2007-087439	20070410
CA, CN, CO, CH, CY, CZ, DE, DK, DM, ES, EG, FR, GB, GR, HU, IL, IN, JP, KR, MA, MD, ME, MG, MK, MN, MU, MY, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, RU, SA, SG, SI, SK, SL, SM, SN, SV, TH, TN, TR, TT, UA, US, VE, VN, ZA, ZM, ZW				
BR A12	BR	20070828	BR 06/000,352	20070828
EP 27, 17, 19, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100				

PRIORITY APPL. INFO.: EP 2006-7454 A 20060407

OTHER SOURCE(S): MARPAT 14748410
 GI




AS The invention relates to compds. of formula I or a pharmaceutically acceptable salt, solvate, solvate, or prodrug thereof. Compds. of formula I wherein Y is (unsubstituted alkyl), (unsubstituted alkenyl),



88 880176-59-0 CAPLUS

CN Benzanilide


N-[4-[(2,5-bis(trifluoromethyl)amino)phenyl]-2-(trifluoromethyl)-2,3-difluorophenyl]-1H-benzimidazole-1-yl]phenyl]-2,3-difluoro- (CA INDEX NAME)



88 880176-91-3 CAPLUS

CN 1H-Benzimidazole-3-carboxylic acid,


1-[4-[(2,5-bis(trifluoromethyl)amino)phenyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



88 880177-08-2 CAPLUS

CN 1H-Benzimidazole-3-carboxylic acid,

1-[4-[(2,5-bis(trifluoromethyl)amino)phenyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



88 880177-28-6 CAPLUS

CN Benzanilide

N-[4-[(5-aminophenyl)-2-(trifluoromethyl)-1H-benzimidazol-1-yl]phenyl]-2,3-difluoro- (CA INDEX NAME)

ACCESSION NUMBER:

DOCUMENT NUMBER:

TITLE:

INVENTOR(S): Benzanilide-1-pyrazine compounds for inflammation

PATENT ASSIGNER(S): Synta Pharmaceuticals Corp., USA

SCOPE:

DOCUMENT TYPE: PCT Int. Appl., 16pp.

LANGUAGE:

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NO 2007103940	A2	20070912	NO 2007-087386	20070210
WI, AE, AG, AU, BR, CA, CH, CN, CO, DE, DK, EP, ES, FI, FR, GB, GR, HK, IL, IN, JP, KR, MA, MX, MY, NL, NO, NZ, PL, PT, RU, SE, SG, SI, SK, TH, TR, TW, UA, US, VE, ZA	INT, AP, EP, JP, KR, MA, MX, MY, NL, NO, NZ, PL, PT, RU, SE, SG, SI, SK, TH, TR, TW, UA, US, VE, ZA	INT, AP, EP, JP, KR, MA, MX, MY, NL, NO, NZ, PL, PT, RU, SE, SG, SI, SK, TH, TR, TW, UA, US, VE, ZA	INT, AP, EP, JP, KR, MA, MX, MY, NL, NO, NZ, PL, PT, RU, SE, SG, SI, SK, TH, TR, TW, UA, US, VE, ZA	INT, AP, EP, JP, KR, MA, MX, MY, NL, NO, NZ, PL, PT, RU, SE, SG, SI, SK, TH, TR, TW, UA, US, VE, ZA

US 20070249403 AL 20071025 US 2007-746079

PRIORITY APPAR. INFO.: P 20060320

CHECKER SOURCE(S): H08RAT 147; 406840

GI

PRIORITY APPAR. INFO.: P 20060320

PRIORITY APPAR. INFO.: P 20060320

PRIORITY APPAR. INFO.: P 20060320

PRIORITY APPAR. INFO.: P 20060320

PRIORITY APPAR. INFO.: P 20060320

PRIORITY APPAR. INFO.: P 20060320

PRIORITY APPAR. INFO.: P 20060320

PRIORITY APPAR. INFO.: P 20060320

PRIORITY APPAR. INFO.: P 20060320

PRIORITY APPAR. INFO.: P 20060320

PRIORITY APPAR. INFO.: P 20060320

PRIORITY APPAR. INFO.: P 20060320

PRIORITY APPAR. INFO.: P 20060320

PRIORITY APPAR. INFO.: P 20060320

PRIORITY APPAR. INFO.: P 20060320

PRIORITY APPAR. INFO.: P 20060320

PRIORITY APPAR. INFO.: P 20060320

PRIORITY APPAR. INFO.: P 20060320

PRIORITY APPAR. INFO.: P 20060320

PRIORITY APPAR. INFO.: P 20060320

PRIORITY APPAR. INFO.: P 20060320

PRIORITY APPAR. INFO.: P 20060320

PRIORITY APPAR. INFO.: P 20060320

PRIORITY APPAR. INFO.: P 20060320


PRIORITY APPAR. INFO.: P 20060320

PRIORITY APPAR. INFO.: P 20060320

PRIORITY APPAR. INFO.: P 20060320

PRIORITY APPAR. INFO.: P 20060320

AB The invention relates to compds. of structural formula 1 or a pharmaceutically acceptable salt, solvate, dihydrate, or prodrug thereof. Compds. of formula 1 wherein R1, R2, and R3 are independently CH3, CH2, and H; R4 is a linker; Y is (un)substituted alkyl; (un)substituted alkyl, (un)substituted allyl, (un)substituted cycloalkyl, (un)substituted



cycoloalkyl, (un)substituted heterocyclyl, and (un)substituted heterocyclyl; each E is independently lower (halo)alkyl, halo, lower alkyl, lower alkylsilyl, CN, NO2, NH2 and derivs., etc.; R1 is a substituent; R4 is H and substituent; a and n are independently 0, 1, and 2, and their pharmaceutically acceptable salts, solvates, dihydrate and prodrugs thereof, are claimed. These compds. are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune diseases. Example compd. II was prepd. by a multistep procedure (procedure given). All the invention compds. were evaluated for their IL-1 inhibitory activity. From the assay, it was detd. that compd. II exhibited an IC50 value of 6 nM.

350844-47-0P
EL PAC (Pharmacological activity); RCT (Reactant); SHM (Synthetic preparation); THP (Therapeutic use); EDC (Biological study); PEP (Preparation); RACT (Reactant or reagent); USES (Uses)

350844-47-0P
EL PAC (Pharmacological activity); RCT (Reactant); SHM (Synthetic preparation); THP (Therapeutic use); EDC (Biological study); PEP (Preparation); RACT (Reactant or reagent); USES (Uses)

350844-47-0P
EL PAC (Pharmacological activity); RCT (Reactant); SHM (Synthetic preparation); THP (Therapeutic use); EDC (Biological study); PEP (Preparation); RACT (Reactant or reagent); USES (Uses)

350844-47-0P
EL PAC (Pharmacological activity); RCT (Reactant); SHM (Synthetic preparation); THP (Therapeutic use); EDC (Biological study); PEP (Preparation); RACT (Reactant or reagent); USES (Uses)

350844-47-0P
EL PAC (Pharmacological activity); RCT (Reactant); SHM (Synthetic preparation); THP (Therapeutic use); EDC (Biological study); PEP (Preparation); RACT (Reactant or reagent); USES (Uses)

350844-47-0P
EL PAC (Pharmacological activity); RCT (Reactant); SHM (Synthetic preparation); THP (Therapeutic use); EDC (Biological study); PEP (Preparation); RACT (Reactant or reagent); USES (Uses)

350844-47-0P
EL PAC (Pharmacological activity); RCT (Reactant); SHM (Synthetic preparation); THP (Therapeutic use); EDC (Biological study); PEP (Preparation); RACT (Reactant or reagent); USES (Uses)

350844-47-0P
EL PAC (Pharmacological activity); RCT (Reactant); SHM (Synthetic preparation); THP (Therapeutic use); EDC (Biological study); PEP (Preparation); RACT (Reactant or reagent); USES (Uses)

350844-47-0P
EL PAC (Pharmacological activity); RCT (Reactant); SHM (Synthetic preparation); THP (Therapeutic use); EDC (Biological study); PEP (Preparation); RACT (Reactant or reagent); USES (Uses)


350844-47-0P
EL PAC (Pharmacological activity); RCT (Reactant); SHM (Synthetic preparation); THP (Therapeutic use); EDC (Biological study); PEP (Preparation); RACT (Reactant or reagent); USES (Uses)

350844-47-0P
EL PAC (Pharmacological activity); RCT (Reactant); SHM (Synthetic preparation); THP (Therapeutic use); EDC (Biological study); PEP (Preparation); RACT (Reactant or reagent); USES (Uses)


350844-47-0P
EL PAC (Pharmacological activity); RCT (Reactant); SHM (Synthetic preparation); THP (Therapeutic use); EDC (Biological study); PEP (Preparation); RACT (Reactant or reagent); USES (Uses)

350844-47-0P
EL PAC (Pharmacological activity); RCT (Reactant); SHM (Synthetic preparation); THP (Therapeutic use); EDC (Biological study); PEP (Preparation); RACT (Reactant or reagent); USES (Uses)


350844-47-0P
EL PAC (Pharmacological activity); RCT (Reactant); SHM (Synthetic preparation); THP (Therapeutic use); EDC (Biological study); PEP (Preparation); RACT (Reactant or reagent); USES (Uses)




950844-49-3 CAPLUS
18-Benzimidazole-5-carboxylic acid,
1-[[1-(2-fluorobenzoyl)amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)




950844-50-3 CAPLUS
18-Benzimidazole-5-carboxylic acid,
1-[[1-(2-methyl-4-pyridinyl)carboxylamino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)




950844-51-6 CAPLUS
18-Benzimidazole-5-carboxylic acid,
1-[[5-[(2-fluorobenzoyl)amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)




950844-53-2 CAPLUS
18-Benzimidazole-5-carboxylic acid,
1-[[5-[(4-chloro-2-fluorobenzoyl)amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)




950844-56-1 CAPLUS
18-Benzimidazole-5-carboxylic acid,
1-[[5-[(2-methylbenzoyl)amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)




950844-57-2 CAPLUS
18-Benzimidazole-5-carboxylic acid,
1-[[5-[(12-methyl-3-pyridinyl)carboxylamino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)




950844-52-7 CAPLUS
18-Benzimidazole-5-carboxylic acid,
1-[[5-[(2,4-difluorobenzoyl)amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)




950844-53-8 CAPLUS
18-Benzimidazole-5-carboxylic acid,
1-[[5-[(2,4-difluorobenzoyl)amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)




950844-54-9 CAPLUS
18-Benzimidazole-5-carboxylic acid,
1-[[5-[(2,7,6-trifluorobenzoyl)amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)




950844-50-3 CAPLUS
18-Benzimidazole-5-carboxylic acid,
1-[[5-[(1-(4-methyl-1,2,3-thiadiazol-5-yl)carboxylamino)-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)




950844-71-0 CAPLUS
18-Benzimidazole-5-carboxylic acid,
1-[[5-[(1-(2,4-difluorophenyl)methyl)amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)




950844-72-1 CAPLUS
18-Benzimidazole-5-carboxylic acid,
1-[[5-[(1-(5-chloro-4-pyridinyl)methyl)amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)




221 95044-73-2 CAPLUS
CN 18-Benzimidazole-5-carboxylic acid,
1-[5-[(2,6-difluorophenyl)methyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)




222 95044-74-3 CAPLUS
CN 18-Benzimidazole-5-carboxylic acid,
1-[5-[(2-fluoro-6-pyridinyl)methyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)




223 95044-75-4 CAPLUS
CN 18-Benzimidazole-5-carboxylic acid,
1-[5-[(2-methyl-6-pyridinyl)methyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)




224 95044-76-5 CAPLUS



225 95044-80-1 CAPLUS
CN 18-Benzimidazole-5-carboxylic acid,
1-[5-[(2-methyl-6-pyridinyl)methyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)




226 95044-81-2 CAPLUS
CN 18-Benzimidazole-5-carboxylic acid,
1-[5-[(2-methyl-6-pyridinyl)methyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)




227 95044-82-3 CAPLUS
CN 18-Benzimidazole-5-carboxylic acid,
1-[5-[(2-methyl-6-pyridinyl)methyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)


CN 18-Benzimidazole-5-carboxylic acid,
1-[5-[(2,5-difluorophenyl)methyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)




228 95044-77-6 CAPLUS
CN 18-Benzimidazole-5-carboxylic acid,
1-[5-[(2,4-difluorophenyl)methyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



229 95044-78-7 CAPLUS
CN 18-Benzimidazole-5-carboxylic acid,
2-(trifluoromethyl)-1-[5-[(2,2,4-trifluorophenyl)methyl]amino]-2-pyrazinyl]-, methyl ester (CA INDEX NAME)




230 95044-79-8 CAPLUS
CN 18-Benzimidazole-5-carboxylic acid,
1-[5-[(2,4-difluorophenyl)methyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)




IT 95044-01-6P 95044-06-TP 95044-07-8P
Rx: RCT (Reactant); SPN (Synthetic Preparation); PREP (Preparation); RACT (Reactant on request)
(Intermediate; preparation of benzimidazolopyrazine comds. useful in treatment and prevention of inflammatory, allergic and immune diseases)


231 95044-05-6 CAPLUS
CN 18-Benzimidazole-5-carboxylic acid,
1-[5-bromo-2-pyrazinyl]-2-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



232 95044-06-7 CAPLUS
CN 18-Benzimidazole-5-carboxylic acid,
1-[5-[(2,4-difluorobenzyl)amino]-2-pyrazinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



233 95044-07-8 CAPLUS
CN 18-Benzimidazole-5-carboxamide, N-(2,2-diethoxyethyl)-1-[5-[(2,4-difluorobenzyl)amino]-2-pyrazinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



1A ANNEX 6 OF 20 CAPLOS COPYRIGHT 2008 ACS on STM
 ACCESSION NUMBER: 2007/704921 CAPLOS
 DOCUMENT NUMBER: 1471105971
 TITLE: Transdermal delivery of pharmaceutical agent comprising genetic molecule
 INVENTOR(S): Russell-Jones, Gregory J.; Lake, Michael E.; Rimes, Stewart E.
 PATENT ASSIGNMENT(S): Apocis Life Sciences Limited, Australia
 SOURCE: PCT Int. Appl., 121pg.
 LAMINATE: COORD. FEEDS
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007076983	A1	20070618	WO 2006/021999	20061222
W, M, AG, AU, AM, AT, AU, BA, BE, BG, BR, BY, CA, CH, CN, CO, CU, CY, CZ, DE, DK, DM, ES, FI, FR, GB, GR, HU, IE, IL, IN, JP, KR, LA, LC, LG, LI, LU, LV, LY, MA, MC, MD, ME, MG, MK, MN, MU, MV, MW, MX, MY, NZ, OM, OS, PA, PE, PG, PH, PL, PT, RU, SA, SE, SG, SI, SK, SL, SM, SN, SV, SW, SY, TH, TN, TR, TT, UA, US, UY, UZ, VC, VN, ZA, ZM, ZW				
AG 2006124870	A1	20070618	AG 2006-324870	20061222
US 20070243122	A1	20071018	US 2006-445172	20061222
EP 1978997	A1	20081015	EP 2006-040407	20061222
FI AT, BE, BG, CH, CY, CZ, DE, DK, ES, FI, FR, GB, GR, HU, IE, IL, IN, JP, KR, LA, LC, LG, LI, LU, LV, LY, MA, MC, MD, ME, MG, MK, MN, MU, MV, MW, MX, MY, NZ, OM, OS, PA, PE, PG, PH, PL, PT, RU, SA, SE, SG, SI, SK, SL, SM, SN, SV, SW, SY, TH, TN, TR, TT, UA, US, UY, UZ, VC, VN, ZA, ZM, ZW				
PRIORITY APPL. INFO.			US 2005-753454P	F 20051212
			WO 2006-905107	A 20060915
			WO 2006-021999	W 20061222

AB The present invention generally relates to a vehicle useful for delivering a pharmaceutically active compound including a genetic mol. or composition. More particularly, the present invention provides microemulsions for transdermal delivery of pharmaceutically active agents to a subject. Thus, stable microemulsion was formed by mixing 14 g of oil (Crodam) and Caprol NCM, at 3:1 ratio) with 4 g of surfactant and co-surfactant (H11 72 and H11 97, at the ratio of 3:1) and stirring until clear. Water phase containing one or more water-soluble pharmaceutical agents was then added (0.5 mL). Microemulsion formation occurred following gentle shaking of the oil and water phases.

TT 68-19-9, Vitamin B12
 RU B07 (Biological study, unclassified); T07 (Therapeutic use); B10L (Biological study); USES (Uses)
 (transdermal delivery of pharmaceutical agent comprising genetic mol.)


BN 68-19-9 CAPLOS

PAGE 1-A

1A ANNEX 6 OF 20 CAPLOS COPYRIGHT 2008 ACS on STM (Continued)
 Cobalamin, alkylated 13422-55-9, Hydroxocobalamin 13422-55-1, Aquacobalamin 13422-55-2, Vitamin B12-600 13422-55-4, Methylcobalamin 13879-90-1, Adenosylcobalamin 14978-39-9, Thiocyanatocobalamin 15041-07-3, Chlorocobalamin 15477-37-9, Sulfatocobalamin 18195-32-9, Vitamin B12-58Co 20623-13-6, Haptocobalamin 24502-77-7, Adenosylpropylcobalamin 4242-97-5, a-(5,6-dimethylbenzimidazolyl)hydroxocobalamin 55565-91-8, Vitamin B12-56Co 54224-23-4, Adenosylmethylcobalamin 59297-78-8, Adenosylmethylcobalamin 114697-40-2
 RU T07 (Therapeutic use); B10L (Biological study); USES (Uses)
 (transdermal delivery of pharmaceutical agent comprising genetic mol.)


BN 68-19-9 CAPLOS
 CN Vitamin B12 (CA INDEX NAME)

PAGE 1-A



PAGE 2-A






BN 13115-Q3-2 CAPLUS
CN Vitamin B12-5'Co (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

BN 13408-T8-1 CAPLUS
CN Cobalamin, dihydrogen phosphate (ester), inner salt, 3'-ester with (5,6-dimethyl-1-methyl-2-thiofuran-2-yl)-18-benzimidazole-4-N3), see (1+) (PCT) (CA INDEX NAME)

PAGE 2-A



BN 13408-T8-1 CAPLUS
CN Cobalamin, dihydrogen phosphate (ester), inner salt, 3'-ester with (5,6-dimethyl-1-methyl-2-thiofuran-2-yl)-18-benzimidazole-4-N3), see (1+) (PCT) (CA INDEX NAME)




BN 13422-53-0 CAPLUS
CN Cobalamin, Co-hydroxy-, C-(4-dihydrogen phosphate), inner salt, 3'-ester with (5,6-dimethyl-1-methyl-2-thiofuran-2-yl)-18-benzimidazole-4-N3)

PAGE 1-A



PAGE 2-A



BN 13422-53-1 CAPLUS
CN Cobalamin, Co-squa-, dihydrogen phosphate (ester), inner salt, 3'-ester

18 ANMEK 6 OF 20 CAPLOS COPYRIGHT 2009 ACS on STM (Continued)
with (5,6-dimethyl-3- α -D-ribofuranosyl-1 β -benzimidazole- α N3),
ion(1+), hydroxide (1-1) (CA INDEX NAME)

PAGE 1-A

18 ANMEK 6 OF 20 CAPLOS COPYRIGHT 2009 ACS on STM (Continued)
PAGE 3-A

• CH⁻

BN 13422-53-2 CAPLOS
CN Vitamin B12-6000 (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

BN 13422-55-4 CAPLOS
CN Cobinamide, Co-methyl-, dihydrogen phosphate (ester), inner salt,
3⁺-ester
with (5,6-dimethyl-3- α -D-ribofuranosyl-1 β -benzimidazole- α N3)
(9C1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



18 ANMEK 6 OF 20 CAPLOS COPYRIGHT 2009 ACS on STM (Continued)

PAGE 2-A




BN 13870-90-1 CAPLOS
CN Cobinamide, Co-(5'-deoxyadenosin-5'-yl)-, 6-(dihydrogen phosphate), inner
salt, 3⁺-ester with (5,6-dimethyl-3- α -D-ribofuranosyl-1 β -
benzimidazole- α N3) (9C1) (CA INDEX NAME)


PAGE 1-A

18 ANMEK 6 OF 20 CAPLOS COPYRIGHT 2009 ACS on STM (Continued)

PAGE 2-A




PAGE 3-A




BN 14978-39-3 CAPLOS
CN Cobinamide, Co-(thioacetate- α N3)-, dihydrogen phosphate (ester),
inner salt, 3⁺-ester with (5,6-dimethyl-3- α -D-ribofuranosyl-1 β -
benzimidazole- α N3) (CA INDEX NAME)






BN 15441-97-3 CAPLUS
CN Cobinamide, Co-oxoboro-, dihydrogen phosphate (ester), inner salt,
3'-ester
with [5,6-dimethyl-1- α -D-ribofuranosyl-18-benzimidazole- α N3]




BN 15471-27-9 CAPLUS
CN Cobinamide, Co-(sulfito- α O)-, dihydrogen phosphate (ester), inner

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

BN 20623-13-6 CAPLUS
CN Cobinamide, Co-(sulfito- α O)-, dihydrogen phosphate (ester), inner
salt, 3'-ester with [5,6-dimethyl-1- α -D-ribofuranosyl-18-
benzimidazole- α N3] (CA INDEX NAME)






```

N23 34502-77-7  CAPLOS
C23 Cobinamide, Co-[3-{6-amino-9H-purin-9-yl)propyl}-, dihydrogen phosphate
      (ester), inner salt, 3'-ester with
      [5,6-dimethyl-1- $\alpha$ -D-ribofuranoyl-1H-benzimidazole-xN3] [CA
      INDEX NAME]

```




PAGE 1-A



PAGE 3-1

Me



HO-C=O



```

EN 41632-95-5 CAPLUS
CN Hydrogenobinamide, dihydrogen phosphate (ester), 3'-ester with
5,6-dimethyl-1- $\alpha$ -D-ribofuranosyl-1H-benzimidazole (CA INDEX NAME)

```




HN 55545-91-8 CAPLUS
 CH Vitamin B12-56Co (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

HN 56238-23-4 CAPLUS
 CH Cobinamide, Co-[5-[6-amino-9H-purin-9-yl]pentyl]-, dihydrogen phosphate (ester), inner salt, 3'-ester with (5,6-dimethyl-3- α -D-ribofuranosyl-1H-benzimidazole-4N3) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




HN 114093-40-2 CAPLUS
 CH Cobinamide, Co-(gamma-CH)-, dihydrogen phosphate (ester), inner salt, 3'-ester with (5-methoxy-6-methyl-3- α -D-ribofuranosyl-1H-benzimidazole-4N3) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




HN 55209-78-8 CAPLUS
 CH Cobinamide, Co-[2-[6-amino-9H-purin-9-yl]ethyl]-, dihydrogen phosphate (ester), inner salt, 3'-ester with (5,6-dimethyl-3- α -D-ribofuranosyl-1H-benzimidazole-4N3) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

(X) 942609-92-9 CASUS
 (Y) 26-Benzimidazol-2-one, 5-[2-(butylthio)acetyl]-1,3-dihydro-1,3-dimethyl-

RL: RCT (Reactant); SYN (Synthetic preparation); PREP (Preparation); M
(Reactant or reagent)
(MTF inhibitors)


18 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)
 CH 2-Pyrimidinamine, N-[4-(4-piperidinylethyl)phenyl]-5-[1(1R)-2-(5-
 (1,1-difluoroethyl)-1R-benzimidazol-7-yl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.



20 337014-32-1 CAPLUS
 CH 1R-Benzimidazol-2-amine, 6-[[1(2R)-3-[2-[[4-(4-
 piperidinylethyl)phenyl]amino]-5-pyrimidinyl]ethyl]- (CA INDEX
 NAME)

Double bond geometry as shown.



20 337015-63-5 CAPLUS
 CH Methanesulfonate acid, 1,1,1-trifluoro-, compd. with
 5-[1(2R)-3-[2-[[4-(4-piperidinylethyl)phenyl]amino]-5-pyrimidinyl]-2-pyrimidinamine (1:1) (CA INDEX NAME)

CH 1

CH2 337013-20-2

CH3 C24 H24 N6 O2 S

Double bond geometry as shown.

18 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)
 ACCESSION NUMBER: 2007033557 CAPLUS
 DOCUMENT NUMBER: 148351385
 TITLE: Cell- and protein-based methods and compositions for
 treatment of tissue defects
 INVENTOR(S): Kleinsch, Donald A.; Sato, Adriana
 PATENT ASSIGNER(S): Kleinsch, Donald, A., USA
 SOURCE: PCT Int. Appl., 342 pp.
 COUNTRY: PAKISTAN
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007035843	A2	20070228	WO 2006-083670	20060921
WO 2007035843	A3	20070705		
US 2007035843	A1	20070705		
US 2007035843	A2	20070705		
US 2007035843	A3	20070705		
US 2007035843	A4	20070705		
US 2007035843	A5	20070705		
US 2007035843	A6	20070705		
US 2007035843	A7	20070705		
US 2007035843	A8	20070705		
US 2007035843	A9	20070705		
US 2007035843	A10	20070705		
US 2007035843	A11	20070705		
US 2007035843	A12	20070705		
US 2007035843	A13	20070705		
US 2007035843	A14	20070705		
US 2007035843	A15	20070705		
US 2007035843	A16	20070705		
US 2007035843	A17	20070705		
US 2007035843	A18	20070705		
US 2007035843	A19	20070705		
US 2007035843	A20	20070705		
US 2007035843	A21	20070705		
US 2007035843	A22	20070705		
US 2007035843	A23	20070705		
US 2007035843	A24	20070705		
US 2007035843	A25	20070705		
US 2007035843	A26	20070705		
US 2007035843	A27	20070705		
US 2007035843	A28	20070705		
US 2007035843	A29	20070705		
US 2007035843	A30	20070705		
US 2007035843	A31	20070705		
US 2007035843	A32	20070705		
US 2007035843	A33	20070705		
US 2007035843	A34	20070705		
US 2007035843	A35	20070705		
US 2007035843	A36	20070705		
US 2007035843	A37	20070705		
US 2007035843	A38	20070705		
US 2007035843	A39	20070705		
US 2007035843	A40	20070705		
US 2007035843	A41	20070705		
US 2007035843	A42	20070705		
US 2007035843	A43	20070705		
US 2007035843	A44	20070705		
US 2007035843	A45	20070705		
US 2007035843	A46	20070705		
US 2007035843	A47	20070705		
US 2007035843	A48	20070705		
US 2007035843	A49	20070705		
US 2007035843	A50	20070705		
US 2007035843	A51	20070705		
US 2007035843	A52	20070705		
US 2007035843	A53	20070705		
US 2007035843	A54	20070705		
US 2007035843	A55	20070705		
US 2007035843	A56	20070705		
US 2007035843	A57	20070705		
US 2007035843	A58	20070705		
US 2007035843	A59	20070705		
US 2007035843	A60	20070705		
US 2007035843	A61	20070705		
US 2007035843	A62	20070705		
US 2007035843	A63	20070705		
US 2007035843	A64	20070705		
US 2007035843	A65	20070705		
US 2007035843	A66	20070705		
US 2007035843	A67	20070705		
US 2007035843	A68	20070705		
US 2007035843	A69	20070705		
US 2007035843	A70	20070705		
US 2007035843	A71	20070705		
US 2007035843	A72	20070705		
US 2007035843	A73	20070705		
US 2007035843	A74	20070705		
US 2007035843	A75	20070705		
US 2007035843	A76	20070705		
US 2007035843	A77	20070705		
US 2007035843	A78	20070705		
US 2007035843	A79	20070705		
US 2007035843	A80	20070705		
US 2007035843	A81	20070705		
US 2007035843	A82	20070705		
US 2007035843	A83	20070705		
US 2007035843	A84	20070705		
US 2007035843	A85	20070705		
US 2007035843	A86	20070705		
US 2007035843	A87	20070705		
US 2007035843	A88	20070705		
US 2007035843	A89	20070705		
US 2007035843	A90	20070705		
US 2007035843	A91	20070705		
US 2007035843	A92	20070705		
US 2007035843	A93	20070705		
US 2007035843	A94	20070705		
US 2007035843	A95	20070705		
US 2007035843	A96	20070705		
US 2007035843	A97	20070705		
US 2007035843	A98	20070705		
US 2007035843	A99	20070705		
US 2007035843	A100	20070705		

AS Materials and methods for treating tissue defects in human or animal
 tissues using implantable cells are described. Further, culture
 techniques and factors for enhancing these procedures, and cell survival
 and adaptation are described. Many of the tissue defects may be treated
 with autologous cells, while applications involving non-autologous cells
 or stem cells are also described.

IT 66-2-9, Vitamin K2
 RI ADV (Adverse effect, including toxicity); RST (Biological study,
 unclassified); RUC (Biological study)
 (cell- and protein-based methods and compositions for tissue defect
 treatment)

HO 68-13-9 CAPLUS
 CH Vitamin K2 (CA INDEX NAME)

18 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)



CH 2

CH3 1493-12-6

CH4 C 8 H 10 O 5





18 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)

PAGE 1-A



PAGE 2-A






IT 887779-01-2P

21 PAC (Pharmacological activity); RCT (Reactant); SPB (Synthetic preparation); TSD (Therapeutic use); BLD (Biological study); PRP (Preparation); RCT (Reactant or reagent); USE (Use) [preparation of octahydroindolo[3,4-c]pyrrole derivs. as histamine H4 receptor ligands]

22 887779-01-3 CAPLUS

23 18-Benzindazole-6-carboxylic acid, 2-[[1,3a,6a,8]-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]carboxyl-, methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 887779-79-2P


887779-79-2P 887779-99-6P 887779-01-3P
887779-04-4P 887779-01-7P 887779-08-1P
887779-12-5P 887779-12-6P 887779-16-0P
887779-21-9P 887779-23-9P 887779-25-3P
887779-27-3P 887779-30-9P 887779-31-9P
887779-22-0P 887779-31-5P 887779-39-7P
887779-40-0P

21 PAC (Pharmacological activity); SPB (Synthetic preparation); TSD (Therapeutic use); BLD (Biological study); PRP (Preparation); USE (Use) [preparation of octahydroindolo[3,4-c]pyrrole derivs. as histamine H4 receptor ligands]

22 887779-79-2 CAPLUS

23 Methanone, [[1,3a,6a,8]-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl][6-methyl-18-benzindazol-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



IT 887779-01-7 CAPLUS

21 Methanone, [[1,3a,6a,8]-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



IT 887779-01-1 CAPLUS

21 Methanone, [[1,3a,6a,8]-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



IT 887779-11-3 CAPLUS

21 Methanone, [[1,3a,6a,8]-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl][6-[[1,4-dimethyl-18-benzindazol-2-yl]]-, rel- (CA INDEX NAME)


Relative stereochemistry.



22 887779-99-4 CAPLUS

23 Methanone, [[1,4-dimethyl-18-benzindazol-2-yl][1,3a,6a,8]-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



22 887779-01-3 CAPLUS

23 Methanone, [[1,3a,6a,8]-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl][7-methyl-18-benzindazol-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



22 887779-04-4 CAPLUS

23 Methanone, [[5-chloro-7-methyl-18-benzindazol-2-yl][1,3a,6a,8]-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



22 887779-12-4 CAPLUS

23 18-Benzindazole-6-carboxylic acid, 2-[[1,3a,6a,8]-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]carboxyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



22 887779-16-0 CAPLUS

23 Methanone, [[6-fluoro-7-methyl-18-benzindazol-2-yl][1,3a,6a,8]-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



22 887779-23-8 CAPLUS


23 Methanone, [[7-fluoro-5-methyl-18-benzindazol-2-yl][1,3a,6a,8]-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




30 887779-23-9 CAPLUS
 CH Methanone, 10-chloro-5-methyl-18-benzimidazol-2-yl [(3aR,6aF)-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl], rel- (CA INDEX NAME)

Relative stereochemistry.




31 887779-25-1 CAPLUS
 CH Methanone, 10-chloro-5-methyl-18-benzimidazol-2-yl [(3aR,6aF)-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl], rel- (CA INDEX NAME)

Relative stereochemistry.




32 887779-27-3 CAPLUS
 CH Methanone, 10-fluoro-5-(trifluoromethyl)-18-benzimidazol-2-yl [(3aR,6aF)-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl], rel- (CA INDEX NAME)

Relative stereochemistry.




33 887779-37-5 CAPLUS
 CH 18-Benzimidazole-2-methanone, 6-(3aR,6aF)-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl-1-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




34 887779-39-7 CAPLUS
 CH 18-Benzimidazole-2-methanone, 6-fluoro-5-(3aR,6aF)-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl-1-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




35 887779-40-0 CAPLUS
 CH 18-Benzimidazole-2-methanone, 6-chloro-5-(3aR,6aF)-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl-1-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




36 887779-30-8 CAPLUS
 CH Methanone, 10-chloro-5-methyl-18-benzimidazol-2-yl [(3aR,6aF)-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl], rel- (CA INDEX NAME)

Relative stereochemistry.




37 887779-31-9 CAPLUS
 CH 18-Benzimidazole-2-methanone, 2-[(3aR,6aF)-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]oxycarbonyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



38 887779-32-0 CAPLUS
 CH Methanone, 10-fluoro-5-(trifluoromethyl)-18-benzimidazol-2-yl [(3aR,6aF)-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl], rel- (CA INDEX NAME)

Relative stereochemistry.



39 3584-63-2 90459-47-9,
 5-Methyl-18-benzimidazole-2-carboxylic acid 673487-31-5
 673487-31-7 795294-04-9 873469-16-0
 873469-20-6 887779-48-8
 RI: RCT (Reactant); RACT (Reactant or reagent)
 [preparation of tetrahydropyrrolo[3,4-c]pyrrole derivative as histamine H4 receptor ligands]
 39 3584-63-2 CAPLUS
 CH 18-Benzimidazole, 5,6-dimethyl-2-(trichloromethyl)- (CA INDEX NAME)



40 99459-47-9 CAPLUS
 CH 18-Benzimidazole-2-carboxylic acid, 6-methyl- (CA INDEX NAME)




41 673487-31-5 CAPLUS
 CH 18-Benzimidazole, 7-methyl-2-(trichloromethyl)- (CA INDEX NAME)




42 673487-33-7 CAPLUS
 CH 18-Benzimidazole, 2-(trichloromethyl)-6-(trifluoromethyl)- (CA INDEX NAME)

LA ANNEX 13 OF 20 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)



FI 886751-84-7 CAPLUS
OH Benzoic acid, B-[5-(6-cyano-2-(4-methoxyphenyl)-1H-benzimidazol-1-yl)pentyl]- (CA INDEX NAME)




IT 582-60-5, 5,6-Dimethylbenzimidazole
R1 ACT (Resistant); RACT (Resistant or resistant)
[Regulation of benzimidazole benzoic acids and their analogs for inhibiting
inflammatory cytokines such as tumor necrosis factor alpha
(TNF-α)]
FI 582-60-5 CAPLUS
OH 1H-Benzimidazole, 5,6-dimethyl- (CA INDEX NAME)



LA ANNEX 14 OF 20 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)

(Biological study)/ USES (Uses)
(Kinase inhibitors for therapeutic use)
FI 31430-18-9 CAPLUS
OH Carbanic acid, B-[(2-(2-thienylcarboxyl)-1H-benzimidazol-2-yl)-, methyl
ester (CA INDEX NAME)



LA ANNEX 14 OF 20 CAPLUS COPYRIGHT 2009 ACS ON STM

ACCESSION NUMBER: 2004-13444 CAPLUS
DOCUMENT NUMBER: 144120140
TITLE: therapeutic uses of kinase inhibitors, and
compositions thereof
INVENTOR(S): Caligaris, Massimo G.; Kley, Nikolai A.; Nuths,
Kathrin E.
PATENT ASSIGNEE(S): GSK Biotech, Inc., USA
SOURCE: PCT Int. Appl., 201 pp.
COMB: F33020
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004020219	A2	2004-01-05	MO 2005-021843	2005-06-17
WO 2004020219	A3	2005-02-12		
Wt: At, Au, Ar, Al, AM, AT, AY, Az, Ba, BB, BG, BR, BY, BF, BS, CA, CH, CN, CO, CU, CY, CZ, DE, DK, DM, EE, EG, ES, FI, FR, GB, GR, HU, IL, IN, JP, KR, KZ, LB, LU, LT, LV, LY, MA, MC, MD, ME, MG, MK, MN, MU, NV, NI, NL, NO, NZ, OC, OM, PG, PE, PL, PT, RU, SE, SG, SI, SK, SL, SM, SV, TH, TM, TN, TR, TT, TW, UA, UG, US, VC, VN, YU, ZA, ZM, ZW				
Rm: AT, BR, BY, BS, CH, CY, CZ, DE, EE, EG, ES, FI, FR, GB, GR, HU, IL, IN, JP, KR, KZ, LB, LU, LT, LV, LY, MA, MC, MD, ME, MG, MK, MN, MU, NV, NI, NL, NO, NZ, OC, OM, PG, PE, PL, PT, RU, SE, SG, SI, SK, SL, SM, SV, TH, TM, TN, TR, TT, TW, UA, UG, US, VC, VN, YU, ZA, ZM, ZW				
Co: CI, CM, CN, CO, CU, CY, CZ, DE, EE, EG, ES, FI, FR, GB, GR, HU, IL, IN, JP, KR, KZ, LB, LU, LT, LV, LY, MA, MC, MD, ME, MG, MK, MN, MU, NV, NI, NL, NO, NZ, OC, OM, PG, PE, PL, PT, RU, SE, SG, SI, SK, SL, SM, SV, TH, TM, TN, TR, TT, TW, UA, UG, US, VC, VN, YU, ZA, ZM, ZW				
CA 2544453	A2	2004-01-05	CA 2005-254463	2005-06-17
EP 1763345	A2	2005-10-21	EP 2005-763355	2005-06-17
Rt: AT, BR, BY, BS, CH, CY, CZ, DE, EE, EG, ES, FI, FR, GB, GR, HU, IL, IN, JP, KR, KZ, LB, LU, LT, LV, LY, MA, MC, MD, ME, MG, MK, MN, MU, NV, NI, NL, NO, NZ, OC, OM, PG, PE, PL, PT, RU, SE, SG, SI, SK, SL, SM, SV, TH, TM, TN, TR, TT, TW, UA, UG, US, VC, VN, YU, ZA, ZM, ZW				
US 2004045555	A2	2004-06-19	US 2007-628338	2007-12-10
PRIORITY APPL. INFO.			US 2004-500649	F 2004-06-18
			WO 2005-021843	W 2005-06-17

OTHER SOURCE(S): MARPAT 144101077
AB The invention pertains to inhibitors of various kinases (e.g. R/T kinases, Tyr kinases, etc.), which inhibitors were previously known as cyclin-dependent kinase inhibitors (CDKs). The inhibitors of the invention are capable of inhibiting various wild-type and mutant form kinases, including drug-resistant forms of mutant kinases. Thus, the kinase inhibitors are useful in treating a wide range of diseases/conditions associated with abnormal kinases/excessive activities of the target kinases, including mutant kinases. The invention further provides methods for treating cancers, tumors, and patients which are resistant or refractory to other therapeutic agents.
Pharmaceutical compns. and packaged pharmaceuticals with instructions of these inhibitors and methods of using these inhibitors
also provided.

IT 31430-18-9, Nucleoside
R1: PAC (Pharmacological activity); TR: (Therapeutic use); R10L


LA ANNEX 15 OF 20 CAPLUS COPYRIGHT 2009 ACS ON STM

ACCESSION NUMBER: 2004-17823 CAPLUS
DOCUMENT NUMBER: 144120140
TITLE: Anti-CD70 antibodies and immunocompates with
therapeutic agents for treatment of cancer and immune
disorders
INVENTOR(S): Law, Cha-Lung; Wahl, Alan F.; Scheller, Nathalie;
Pattaya, Linda A.
PATENT ASSIGNEE(S): Seattle Genetics, Inc., USA
SOURCE: PCT Int. Appl., 159 pp.
COMB: F33020
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004073656	A2	2004-09-02	MO 2004-095247	2004-02-20
WO 2004073656	A3	2005-02-24		
WO 2004073656	A9	2005-09-01		
Wt: At, Au, Ar, Al, AM, AT, AY, Az, Ba, BB, BG, BR, BY, BF, BS, CA, CH, CN, CO, CU, CY, CZ, DE, EE, EG, ES, FI, FR, GB, GR, HU, IL, IN, JP, KR, KZ, LB, LU, LT, LV, LY, MA, MC, MD, ME, MG, MK, MN, MU, NV, NI, NL, NO, NZ, OC, OM, PG, PE, PL, PT, RU, SE, SG, SI, SK, SL, SM, SV, TH, TM, TN, TR, TT, TW, UA, UG, US, VC, VN, YU, ZA, ZM, ZW				
Rm: AT, BR, BY, BS, CH, CY, CZ, DE, EE, EG, ES, FI, FR, GB, GR, HU, IL, IN, JP, KR, KZ, LB, LU, LT, LV, LY, MA, MC, MD, ME, MG, MK, MN, MU, NV, NI, NL, NO, NZ, OC, OM, PG, PE, PL, PT, RU, SE, SG, SI, SK, SL, SM, SV, TH, TM, TN, TR, TT, TW, UA, UG, US, VC, VN, YU, ZA, ZM, ZW				
AD 2004213053	A1	2004-09-02	AD 2004-213053	2004-02-20
CA 2316445	A2	2004-09-02	CA 2004-231645	2004-02-20
EP 1934542	A2	2005-11-16	EP 2004-713441	2004-02-20
Rt: AT, BR, BY, BS, CH, DE, EE, EG, ES, FI, FR, GB, GR, HU, IL, IN, JP, KR, KZ, LB, LU, LT, LV, LY, MA, MC, MD, ME, MG, MK, MN, MU, NV, NI, NL, NO, NZ, OC, OM, PG, PE, PL, PT, RU, SE, SG, SI, SK, SL, SM, SV, TH, TM, TN, TR, TT, TW, UA, UG, US, VC, VN, YU, ZA, ZM, ZW				
JP 2005187513	F	2004-06-17	JP 2004-050790	2004-02-20
US 20040233794	A1	2004-10-19	US 2005-546304	2005-09-19
US 2005022899	A2	2005-03-31	US 2003-735430	2003-07-23
PRIORITY APPL. INFO.			US 2003-449055P	F 2003-02-20
			WO 2004-025247	A 2004-02-20
			US 2005-546304	A2 2005-09-19
			US 2006-793227P	P 2006-04-13

AB Disclosed are anti-CD70 antibodies and derivs. thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immune disorders, comprising administering to a subject the disclosed pharmaceutical compositions.


IT 31430-18-9, Nucleoside, conjugates
(Biological study)/ USES (Uses)
(Anti-CD70 antibodies and immunocompates with therapeutic agents for treatment of cancer and immune disorders)
FI 31430-18-9 CAPLUS
OH Carbanic acid, B-[(2-(2-thienylcarboxyl)-1H-benzimidazol-2-yl)-, methyl
ester (CA INDEX NAME)




RI 710244-04-2 CAPLUS
 CN 26-benzimidazol-2-one, 5-[(12,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohept-5-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)propyl]- (CA INDEX NAME)



RI 710244-05-1 CAPLUS
 CN 26-benzimidazol-2-one, 5-[(12,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohept-5-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)propyl]- (CA INDEX NAME)




RI 710244-06-2 CAPLUS
 CN 26-benzimidazol-2-one, 5-[(12,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohept-5-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)propyl]- (CA INDEX NAME)




RI 710244-14-2 CAPLUS
 CN 26-benzimidazol-2-one, 5-[(12,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohept-5-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)propyl]- (CA INDEX NAME)

Double bond geometry as shown.




RI 710244-17-5 CAPLUS
 CN 26-benzimidazol-2-one, 5-[(12,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohept-5-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)propyl]- (CA INDEX NAME)

Double bond geometry as shown.




RI 710244-18-6 CAPLUS
 CN 26-benzimidazol-2-one, 5-[(12,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohept-5-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)propyl]- (CA INDEX NAME)



RI 710244-08-4 CAPLUS
 CN 18-benzimidazol-2-one, 6-[(10,11-dihydro-5H-dibenzo[a,d]cyclohept-5-ylidene)methyl]- (CA INDEX NAME)




RI 710244-10-8 CAPLUS
 CN 18-benzimidazol-2-one, 6-[(10,11-dihydro-5H-dibenzo[a,d]cyclohept-5-ylidene)methyl]- (CA INDEX NAME)




RI 710244-13-1 CAPLUS
 CN 28-benzimidazol-2-one, 5-[(12,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohept-5-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)propyl]- (CA INDEX NAME)

Double bond geometry as shown.




RI 710244-19-7 CAPLUS
 CN 28-benzimidazol-2-one, 5-[(12,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohept-5-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)propyl]- (CA INDEX NAME)




RI 710244-20-0 CAPLUS
 CN 5H-Dibenzo[a,d]cycloheptene-2-carbonitrile, 5-[(12,3-dihydro-2-oxo-18-benzimidazol-5-yl)methylene]-10,11-dihydro-1,3-dihydro-1-[2-(4-morpholinyl)propyl]- (CA INDEX NAME)

Double bond geometry as shown.




RI 710244-21-3 CAPLUS
 CN 5H-Dibenzo[a,d]cycloheptene-2-carbonitrile, 5-[(12,3-dihydro-2-oxo-18-benzimidazol-5-yl)methylene]-10,11-dihydro-1,3-dihydro-1-[2-(4-morpholinyl)propyl]- (CA INDEX NAME)

Double bond geometry as shown.




FN 710344-24-4 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(12,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)




FN 710344-26-6 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(12,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)

Double bond geometry as shown.




Double bond geometry as shown.




FN 710344-31-3 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(12,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)

Double bond geometry as shown.




FN 710344-35-7 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(12,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)




FN 710344-37-9 CAPLUS

FN 710344-27-7 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(12,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)


Double bond geometry as shown.



FN 710344-28-8 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(12,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)




FN 710344-29-9 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(12,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)




FN 710344-30-2 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(12,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)

Double bond geometry as shown.




FN 710344-38-0 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(12,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)

Double bond geometry as shown.




FN 710344-51-7 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(12,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)

Double bond geometry as shown.




18 ANSWER 16 OF 20 CAPLUS COPTXSET 2009 ACS ON STN (Continued)


RU 710344-75-5 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(8-fluoro-10,11-dihydro-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RU 710345-04-3 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(2-chloro-7-fluoro-4,5-dihydro-10H-benzo[4,5]cyclohepta[1,2-d]thiazol-10-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)




RU 710345-27-0 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(4,5-dihydro-10H-benzo[4,5]cyclohepta[1,2-d]thiazol-10-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)




RU 710345-33-0 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(8)-(7-fluoro-4,5-dihydro-10H-benzo[4,5]cyclohepta[1,2-d]thiazol-10-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)


18 ANSWER 16 OF 20 CAPLUS COPTXSET 2009 ACS ON STN (Continued)



RU 710345-66-7 CAPLUS
CN 28-Benzimidazol-2-one, 1-cyclopropyl-5-[(8-fluoro-10,11-dihydro-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)




RU 710345-69-0 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(8-fluoro-10,11-dihydro-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RU 710345-76-9 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(3-fluorodibenz[b,e]azepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)


18 ANSWER 16 OF 20 CAPLUS COPTXSET 2009 ACS ON STN (Continued)

Double bond geometry as shown.




RU 710345-37-2 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(12)-(7-fluoro-4,5-dihydro-10H-benzo[4,5]cyclohepta[1,2-d]thiazol-10-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.




RU 710345-64-5 CAPLUS
CN 5H-Benzo[4,5]cyclohepta[1,2-b]pyridine-2-carbonitrile, 5-[(1,3-dihydro-2-oxo-1H-benzimidazol-5-yl)methylidene]-8-fluoro-10,11-dihydro- (CA INDEX NAME)




RU 710345-65-6 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(8-fluoro-10,11-dihydro-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-ylidene)methyl]-1,3-dihydro-1-(1-methylethyl)- (CA INDEX NAME)




18 ANSWER 16 OF 20 CAPLUS COPTXSET 2009 ACS ON STN (Continued)




RU 710345-77-0 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(3-fluorodibenz[b,e]azepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)




RU 710345-78-1 CAPLUS
CN 28-Benzimidazol-2-one, 1-cyclopropyl-5-[(3-fluorodibenz[b,e]azepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)




RU 710345-79-2 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(3-fluorodibenz[b,e]azepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)




RI 710245-80-5 CAPLOS
CN 28-Benzimidazol-2-one, 5-[(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[1-methylethyl]- (CA INDEX NAME)



RI 710245-81-6 CAPLOS
CN 28-Benzimidazol-2-one, 5-[(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)




RI 710245-82-7 CAPLOS
CN 28-Benzimidazol-2-one, 5-[(3-chlorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)




RI 710245-84-1 CAPLOS
CN 28-Benzimidazol-2-one, 5-[(2)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)


Double bond geometry as shown.




RI 710245-92-9 CAPLOS
CN 28-Benzimidazol-2-one, 5-[(2)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)




RI 710245-97-0 CAPLOS
CN 28-Benzimidazol-2-one, 5-[(2)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)




RI 710245-83-8 CAPLOS
CN 28-Benzimidazol-2-one, 5-[(2)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)



RI 710245-84-9 CAPLOS
CN 28-Benzimidazol-2-one, 5-[(2)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)




RI 710245-85-0 CAPLOS
CN 28-Benzimidazol-2-one, 5-[(2)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)




RI 710246-00-2 CAPLOS
CN 28-Benzimidazol-2-one, 5-[(2)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)


Double bond geometry as shown.




RI 710246-01-3 CAPLOS
CN 28-Benzimidazol-2-one, 5-[(2)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)




RI 710246-04-6 CAPLOS
CN 28-Benzimidazol-2-one, 5-[(2)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-methyl- (CA INDEX NAME)




RI 710346-06-8 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(8-chlorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)




RI 710346-07-8 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(4-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RI 710346-08-0 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(11a-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)




RI 710346-12-6 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(13-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RI 710346-13-7 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(13-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-methylpropyl]- (CA INDEX NAME)

Double bond geometry as shown.




RI 710346-14-8 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(13-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-methylpropyl]- (CA INDEX NAME)


Double bond geometry as shown.




RI 710346-09-1 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(13-fluoro-4,11-dihydrodibenz[b,e]oxepin-11-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)




RI 710346-10-4 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(13-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RI 710346-11-5 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(13-chlorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RI 710346-15-9 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(13-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RI 710346-16-0 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(13-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)



RI 710346-17-1 CAPLUS
CN 28-Benzimidazol-2-one, 5-[(13-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



AB Title compds. I [X = O, S, alkyl, arino; Y = amino, O, S, alkyl; Z = CH₃, CH₃, imino, SO, RO₂; R₁ = H, alkyl, alkenyl, etc.; R₂ = alkyl, alkenyl, alkynyl, etc.; R₃ = H, alkyl, alkenyl, arino, alkylalkenyl, etc.; R₄ = H, alkyl, alkenyl, alkynyl, etc.] are prepared. For instance, 1,4-dioxolane is reacted with urea (pentanol, reflux) to give 5-methylbenzimidazol-2-one (56). Example compds. are inhibitors of the cytochrome or biol. activity of macrophage migration inhibitory factor (MIF). I are useful for the treatment of Lyme disease, connective tissue diseases, etc.

IT 1420-75-2P 13014-14-4P 67014-36-3P 57571-42-2P 634602-81-2P 634602-81-2P
R₁ PAC (Pharmacological activity); RCT (Reaction); SPH (Synthetic preparation); TEP (Therapeutic use); BIO (Biological study); PREP (Preparation); RACT (Reaction or reaction); USES (Uses)
[Preparation of substituted benzimidazoles which inhibit the cytochrome or biol. activity of macrophage migration inhibitory factor (MIF)]

RU 1420-75-2 CAPLOS
CN 28-Benzimidazol-2-one, 1,3-dihydro-5-methyl- (CA INDEX NAME)




RU 13014-14-4 CAPLOS
CN 18-Benzimidazol-2-one, 2,3-dihydro-2-oxo-1-methyl- (CA INDEX NAME)



RU 67014-36-2 CAPLOS
CN 28-Benzimidazol-2-one, 5-amino-1,3-dihydro-6-methyl- (CA INDEX NAME)

18 ANSWER 17 OF 20 CAPLOS COPYRIGHT 2008 ACS on STN (Continued)
[Therapeutic use]; BIO (Biological study); PREP (Preparation); USES (Uses)
[Prep. of substituted benzimidazoles which inhibit the cytochrome or biol. activity of macrophage migration inhibitory factor (MIF)]


RU 16949-35-2 CAPLOS
CN 18-Benzimidazol-2-one, 2,3-dihydro-8,9-dioxo- (CA INDEX NAME)



RU 58689-25-1 CAPLOS
CN 18-Benzimidazol-2-one, 2,3-dihydro-8,9-dioxo- (CA INDEX NAME)



RU 100233-32-3 CAPLOS
CN 28-Benzimidazol-2-one, 1,3-dihydro-1-pentyl- (CA INDEX NAME)



RU 106419-57-6 CAPLOS
CN 18-Benzimidazol-2-one, 2,3-dihydro-2-oxo-1-methyl- (CA INDEX NAME)



RU 634602-82-7 CAPLOS
CN 18-Benzimidazol-2-one, 2,3-dihydro-2-oxo-1-pentyl- (CA INDEX NAME)




RU 83573-62-0 CAPLOS
CN 28-Benzimidazol-2-one, 1,3-dihydro-5-methyl-4-nitro- (CA INDEX NAME)




RU 634602-81-0 CAPLOS
CN 18-Benzimidazol-2-one, 2,3-dihydro-2-oxo-18-benzimidazol-5-yl carbonyl- (CA INDEX NAME)

Absolute stereochemistry.




RU 634602-87-2 CAPLOS
CN 18-Benzimidazol-2-one, 2,3-dihydro-2-oxo-18-benzimidazol-5-yl carbonyl- (CA INDEX NAME)


Absolute stereochemistry.



IT 36894-35-2P 58689-25-1P 100233-32-3P 106419-57-6P 634602-82-7P 634602-83-8P 634602-84-9P 634602-86-1P 634602-88-3P 634602-89-4P 634602-90-7P 634602-91-8P 634602-92-9P 634602-93-2P 634602-94-3P 634602-95-2P 634602-96-3P 634602-97-4P 634602-98-2P
R₁ PAC (Pharmacological activity); SPH (Synthetic preparation); TEP (Therapeutic use)



RU 634602-83-8 CAPLOS
CN 18-Benzimidazol-2-one, 2,3-dihydro-2-oxo-18-benzimidazol-5-yl carbonyl- (CA INDEX NAME)




RU 634602-84-9 CAPLOS
CN 18-Benzimidazol-2-one, 2,3-dihydro-2-oxo-18-benzimidazol-5-yl carbonyl- (CA INDEX NAME)



RU 634602-86-1 CAPLOS
CN 18-Benzimidazol-2-one, 2,3-dihydro-2-oxo-18-benzimidazol-5-yl carbonyl- (CA INDEX NAME)


Absolute stereochemistry.




RU 634602-88-3 CAPLOS
CN 18-Benzimidazol-2-one, 2,3-dihydro-2-oxo-18-benzimidazol-5-yl carbonyl- (CA INDEX NAME)

Absolute stereochemistry.


18 ANEXER 17 OF 20 CAPLOS COPYRIGHT 2008 ACS ON STM (Continued)



RU 634602-89-4 CAPLOS
CN 18-Benzimidazole-5-carboxamide, N-([2,4-dihydroxyphenyl]ethyl)-2,3-dihydro-2-oxo- (CA INDEX NAME)




RU 634602-90-7 CAPLOS
CN 18-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-thioxo-, pentyl ester (CA INDEX NAME)




RU 634602-91-3 CAPLOS
CN 18-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-thioxo-, pentyl ester (CA INDEX NAME)

Absolute stereochemistry.




RU 634602-92-9 CAPLOS
CN 18-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-thioxo-, pentyl ester (CA INDEX NAME)

18 ANEXER 17 OF 20 CAPLOS COPYRIGHT 2008 ACS ON STM (Continued)



RU 634602-93-2 CAPLOS
CN 18-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-thioxo-, pentyl ester (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.

FORMAT


18 ANEXER 17 OF 20 CAPLOS COPYRIGHT 2008 ACS ON STM (Continued)



RU 634602-93-2 CAPLOS
CN 18-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-thioxo-, pentyl ester (CA INDEX NAME)




RU 634602-94-3 CAPLOS
CN 18-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-thioxo-, pentyl ester (CA INDEX NAME)



RU 634602-95-2 CAPLOS
CN 18-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-thioxo-, pentyl ester (CA INDEX NAME)



RU 634602-96-3 CAPLOS
CN 18-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-thioxo-, pentyl ester (CA INDEX NAME)



RU 634602-97-4 CAPLOS
CN 18-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-thioxo-, pentyl ester (CA INDEX NAME)

18 ANEXER 18 OF 20 CAPLOS COPYRIGHT 2008 ACS ON STM (Continued)

DOCUMENT NUMBER: 138314583
TITLE: Methods using highly effective inhibition of the renin-angiotensin system for protecting tissue from the effects of angiotensin II
INVENTOR(S): USA
PATENT ASSIGNEE(S): U.S. Pat. Appl. Publ., 39 pp.
SOURCE: CODE: US2000
LANGUAGE: Patent
FAMILY ACC. NUM. COUNTRY: English
PATENT INFORMATION: 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030078190	A1	20030424	US 2002-155824	20020524
PRIORITY APPL. INFO.			US 2001-292825P	P 20010525

AB Methods and pharmaceutical compns. are provided for protecting tissue of a subject from the effects of angiotensin II. The methods involve administering to subjects angiotensin receptor blockers (ARB), either by themselves at doses beyond those recommended or effective for the management of hypertension, or in combination with angiotensin-converting enzyme inhibitors (ACEI). The pharmaceutical compns. include both an ARB and an ACEI and are formulated in certain preferred embodiments for once-daily oral administration. The methods and pharmaceutical compns. are useful for the treatment of proteinuria, chronic or congestive heart failure, aneurysm, and vascular tissue hypotrophy.


17 137481-59-7, Candesartan 137481-59-70, Candesartan, prodrug deriva. 144701-48-4, Telmisartan 144701-48-4, Telmisartan, prodrug deriva. 145040-77-5, Candesartan cilexetil 145040-77-5 (Pharmacological activity); 756 (Therapeutic use); 870 (Biological study); US28 (Uses)

effects of renin-angiotensin system inhibition for protecting tissue from effects of angiotensin II


RU 137481-59-7 CAPLOS
CN 18-Benzimidazole-5-carboxylic acid, 2-ethoxy-3-[[[2'-[28-tetraol-5-yl]1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RU 137481-59-7 CAPLOS
CN 18-Benzimidazole-5-carboxylic acid, 2-ethoxy-3-[[[2'-[28-tetraol-5-yl]1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




FI 144701-48-4 CAPLOS
CH 1,1'-Bis(4-oxo-1,2,3,4-tetrahydro-1H-benzimidazol-2-yl)-4,4'-biphenyl-1,1'-dicarboxylic acid,
4'-(1,1',4'-dimethyl-1,2'-propryl[2,4'-bi-18-benzimidazol]-1'-yl)methyl- (CA INDEX NAME)




FI 144701-48-4 CAPLOS
CH 1,1'-Bis(4-oxo-1,2,3,4-tetrahydro-1H-benzimidazol-2-yl)-4,4'-biphenyl-1,1'-dicarboxylic acid,
4'-(1,1',4'-dimethyl-1,2'-propryl[2,4'-bi-18-benzimidazol]-1'-yl)methyl- (CA INDEX NAME)



PAGE 2-A



FI 145040-77-5 CAPLOS
CH 18-Benzimidazole-7-carboxylic acid,
2-ethoxy-7-[[2'-[18-tetrazol-5-yl]1,1'-biphenyl]-4-yl)methyl]-,
1-[[[cyclohexyl]carbonyl]oxy]ethyl ester (CA INDEX NAME)



PAGE 1-A

LA ANSWER 19 OF 20 CAPLOS COPYRIGHT 2009 ACS ON STN
ACCESSION NUMBER: 1999-019234
DOCUMENT NUMBER: 132459191
TITLE: Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
INVENTOR(S): Lai, Ching-San; Vassilev, Vassil
PATENT ASSIGNOR(S): Medinex, Inc.; USA
SOURCE: PCT Int. Appl., 102 pp.
DOCUMENT TYPE: OTHER: P13020
LANGUAGE: Patent
FAMILY ACC. NUM. COUNTRY: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9966918	A1	1999-12-29	WO 1999-081437	1999-06-22
Wt: AU, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GR, GU, HK, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LA, LB, LG, LI, LU, LV, MD, MG, MN, MU, MW, MY, NI, NL, NO, NZ, PE, PG, PH, PK, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TM, TR, TT, TH, TN, TS, US, UZ, VN, YU, ZA, ZW				
Wt: GB, GM, GR, IL, IS, IT, JP, KE, KG, KP, KR, KZ, LA, LB, LG, LI, LU, LV, MD, MG, MN, MU, MW, MY, NI, NL, NO, NZ, PE, PG, PH, PK, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TM, TR, TT, TH, TN, TS, US, UZ, VN, YU, ZA, ZW				
US 6037473	A	2000-07-25	US 1998-106739	1999-06-22
CA 2358668	A1	1999-12-29	CA 1999-235868	1999-06-22
AD 9947119	A	2000-01-10	AD 1999-47119	1999-06-22
AD 762080	B2	2000-07-03		
EP 1089723	A2	2001-04-11	EP 1999-830617	1999-06-22
Rt: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 200218441	T	2000-06-25	JP 2000-55604	1999-06-22
US 0216562	B1	2001-11-13	US 2000-56566	2000-05-05
PRIORITY AFFILI. INFO.:			US 1998-106739	A2 1999-06-22
			WO 1999-081437	Y 1999-06-22

OTHER SOURCE(S): MARPAT 132:59191
AB The invention provides a dithiocarbamate disulfide dimer useful in various therapeutic treatments, either alone or in combination with other active agents. In one method, the disulfide derivative of a dithiocarbamate is administered with an agent that inactivates (or inhibits the production of) species that induce the expression of nitric oxide synthase to reduce the production of such species, while, at the same time reducing nitric oxide levels in the subject. In another embodiment, free iron ion levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate to sequester free iron ions, for example, in subjects undergoing orthotopic liver chemotherapy. In another embodiment, cyanide levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate so as to bind cyanide in the subject. In a further aspect, the present invention relates to compounds and formulations useful in such therapeutic methods.
IT 1312-51-2, Hydroxocobalamin
Rt: R0C (Biological activity or effector, except adverse); B01 (Biological)


18 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)
 RE: FCT (Reactant); SYN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 [prepn. of substituted atom, compds. as inhibitors of tumor necrosis factor and GMP phosphodiesterase]
 RE 201287-02-8 CAPLUS
 CN 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(methoxymethyl)- (CA INDEX NAME)



RE 201287-04-9 CAPLUS
 CN 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-phenyl- (CA INDEX NAME)



RE 201287-05-0 CAPLUS
 CN 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(2-phenylethyl)- (CA INDEX NAME)




RE 201287-06-1 CAPLUS
 CN 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(phenylmethyl)- (CA INDEX NAME)



18 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)
 INDEX NAME)




RE 201287-11-8 CAPLUS
 CN 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)



RE 201287-11-3 CAPLUS
 CN 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(3-phenylbutyl)- (CA INDEX NAME)



RE 201287-13-0 CAPLUS
 CN 18-Benzimidazole-4-carboxylic acid, 2-[(4-bromophenyl)methyl]-7-methoxy- (CA INDEX NAME)



RE 201287-14-1 CAPLUS


18 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)



RE 201287-07-2 CAPLUS
 CN 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(1-phenylethyl)- (CA INDEX NAME)



RE 201287-08-3 CAPLUS
 CN 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-[4-methoxyphenyl)methyl]- (CA INDEX NAME)




RE 201287-09-4 CAPLUS
 CN 18-Benzimidazole-4-carboxylic acid, 2-(1,2-diphenylethyl)-7-methoxy- (CA INDEX NAME)




RE 201287-10-7 CAPLUS
 CN 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(2-phenylpropyl)- (CA INDEX NAME)




18 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)
 CN 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(3-methoxy-3-phenylpropyl)- (CA INDEX NAME)



RE 201287-15-2 CAPLUS
 CN 18-Benzimidazole-4-carboxylic acid, 2-[(4-oxanaphenyl)methyl]-7-methoxy- (CA INDEX NAME)



RE 201287-16-3 CAPLUS
 CN 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-[(4-(2-pyridyl)phenyl)methyl]- (CA INDEX NAME)



RE 201287-17-4 CAPLUS
 CN 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-[(2-methoxyphenyl)methyl]- (CA INDEX NAME)



18 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RI 201297-19-5 CAPLUS
 CH 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(methoxyphenylmethyl)- (CA INDEX NAME)



RI 201297-19-9 CAPLUS
 CH 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-methyl- (CA INDEX NAME)



RI 201297-21-2 CAPLUS
 CH 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(phenoxymethyl)- (CA INDEX NAME)



RI 201297-21-1 CAPLUS
 CH 18-Benzimidazole-4-carboxylic acid, 2-cyclopentyl-7-methoxy- (CA INDEX NAME)




18 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
 CH 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(methoxymethyl)-, methyl ester (CA INDEX NAME)



RI 201297-28-7 CAPLUS
 CH 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-phenyl-, methyl ester (CA INDEX NAME)



RI 201297-29-8 CAPLUS
 CH 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-[2-phenylethyl]-, methyl ester (CA INDEX NAME)



RI 201297-30-1 CAPLUS
 CH 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(phenylmethyl)-, methyl ester (CA INDEX NAME)

18 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RI 201297-23-2 CAPLUS
 CH 18-Benzimidazole-7-carboxylic acid, 2-(phenylmethyl)- (CA INDEX NAME)



RI 201297-24-3 CAPLUS
 CH 18-Benzimidazole-6-carboxylic acid, 2-cyclopentyl-7-methoxy-1-methyl- (CA INDEX NAME)



RI 201297-25-4 CAPLUS
 CH 18-Benzimidazole-6-carboxylic acid, 2,7-dimethoxy- (CA INDEX NAME)



RI 201297-26-5 CAPLUS
 CH 18-Benzimidazole-6-carboxylic acid, 2-cyclopropyl-7-methoxy- (CA INDEX NAME)



RI 201297-27-6 CAPLUS


18 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RI 201297-31-2 CAPLUS
 CH 18-Benzimidazole-6-carboxylic acid, 7-methoxy-2-(1-phenylethyl)-, methyl ester (CA INDEX NAME)



RI 201297-32-3 CAPLUS
 CH 18-Benzimidazole-6-carboxylic acid, 7-methoxy-2-[(4-methoxyphenyl)methyl]-, methyl ester (CA INDEX NAME)




RI 201297-33-4 CAPLUS
 CH 18-Benzimidazole-6-carboxylic acid, 2-(cyclohexylphenylmethyl)-7-methoxy-, methyl ester (CA INDEX NAME)






RI 201287-34-5 CAPLUS
CI 18-Benzimidazole-4-carboxylic acid, 2-[(1,2-diphenylethyl)-7-methoxy-, methyl ester (CA INDEX NAME)



RI 201287-35-6 CAPLUS
CI 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(2-phenylpropyl)-, methyl ester (CA INDEX NAME)




RI 201287-36-7 CAPLUS
CI 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-[(4-methoxyphenyl)methyl]-, methyl ester (CA INDEX NAME)




RI 201287-42-3 CAPLUS
CI 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-[(2-methoxyphenyl)methyl]-, methyl ester (CA INDEX NAME)



RI 201287-41-4 CAPLUS
CI 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-[(2-methoxyphenyl)methyl]-, methyl ester (CA INDEX NAME)




RI 201287-42-5 CAPLUS
CI 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-methyl-, methyl ester (CA INDEX NAME)



RI 201287-37-8 CAPLUS
CI 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(3-phenylbutyl)-, methyl ester (CA INDEX NAME)



RI 201287-38-9 CAPLUS
CI 18-Benzimidazole-4-carboxylic acid, 2-[(4-bromophenyl)methyl]-7-methoxy-, methyl ester (CA INDEX NAME)



RI 201287-39-0 CAPLUS
CI 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(3-methoxy-3-phenylpropyl)-, methyl ester (CA INDEX NAME)



RI 201287-43-6 CAPLUS
CI 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(phenoxymethyl)-, methyl ester (CA INDEX NAME)



RI 201287-44-7 CAPLUS
CI 18-Benzimidazole-4-carboxylic acid, 2-oxopentyl-7-methoxy-, methyl ester (CA INDEX NAME)



RI 201287-45-8 CAPLUS
CI 18-Benzimidazole-4-carboxylic acid, 2-(phenylmethyl)-, methyl ester (CA INDEX NAME)



20 201297-66-9 CAPLUS
CN 18-Benzimidazole-4-carboxylic acid, 2-cyclopentyl-7-methoxy-, methyl ester (CA INDEX NAME)




20 201297-67-4 CAPLUS
CN 18-Benzimidazole-6-carboxylic acid, 2-cyclopentyl-7-methoxy-1-methyl-, methyl ester (CA INDEX NAME)




20 201297-68-5 CAPLUS
CN 18-Benzimidazole-7-carboxylic acid, 2-cyclopentyl-4-methoxy-1-methyl-, methyl ester (CA INDEX NAME)



20 201297-76-5 CAPLUS
CN 18-Benzimidazole-4-carboxylic acid, 2-[(4-cyanophenyl)methyl]-7-methoxy-, methyl ester (CA INDEX NAME)



20 201297-77-6 CAPLUS
CN 18-Benzimidazole-6-carboxylic acid, 7-methoxy-2-[(4-(3-pyridyl)phenyl)methyl]-, methyl ester (CA INDEX NAME)



20 201441-55-8 CAPLUS
CN 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-[(3-methoxyphenyl)methyl]- (CA INDEX NAME)



20 201297-69-6 CAPLUS
CN 18-Benzimidazole-6-carboxylic acid, 2,7-dimethoxy-, methyl ester (CA INDEX NAME)



20 201297-74-3 CAPLUS
CN 18-Benzimidazole-6-carboxylic acid, 7-methoxy-2-(methoxyphenylmethyl)-, methyl ester (CA INDEX NAME)



20 201297-75-4 CAPLUS
CN 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(3-pyridyl)-, methyl ester (CA INDEX NAME)



20 201441-56-9 CAPLUS
CN 18-Benzimidazole-6-carboxylic acid, 7-methoxy-2-(methoxymethyl)- (CA INDEX NAME)



20 201441-57-0 CAPLUS
CN 18-Benzimidazole-6-carboxylic acid, 2-(cyclohexylphenylmethyl)-7-methoxy- (CA INDEX NAME)



20 201441-58-1 CAPLUS
CN 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(1-methylthio)- (CA INDEX NAME)



LA ANSWER 20 OF 20 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)
 REF DOI:10.1021/ja081411a020 CAPLUS
 CH 12-Benzimidazole-6-carboxylic acid, 7-methoxy-2-(1-methylethyl)-, methyl
 ester (CA INDEX TERMS)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE EE
 FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

119.88

298.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-16.00

-16.00

STN INTERNATIONAL LOGOFF AT 13:12:14 ON 18 NOV 2008